In its latest bid to address the opioid epidemic, the Food and Drug Administration released a so-called final guidance document that is designed to help drug makers develop generic versions of abuse-deterrent painkillers.

By encouraging production of such medicines, the agency hopes to mitigate the extent to which individuals misuse opioids while simultaneously lowering prescription drug costs, a wider goal that FDA officials have adopted in recent months.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • From Canada they know what’s right!!!! USA unethical and will make pain patients who abide by all the rules of pain contract and have never done anything wrong! It’s inhumane!

    #opioidhysteria #chronicpain #spoonies BIG NEWS FROM CANADA! Provence of British Columbia reversed CDC and PROP David Juurlink requiring all physicians TO TREAT ALL PAIN PATIENTS WITHOUT DOSAGE RESTRICTIONS and to stop EXCLUDING pain patients from their practices.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy